AnalystBook Research · Company Intelligence

Fortive Corp

FTVNYSE

Built from Fortive Corp's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Fortive produced modest growth, higher profit and strong free cash flow, but cash conversion softened as portfolio investment continued.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 1.9%OK
  • ProfitabilityNet income declined 30.5% to $579.2M from $832.9MWatch
  • Cash flowFree cash flow declined 32.1% to $978.1M from $1.441BWatch
  • MarginsOperating margin contracted 23 bps to 17.32%Watch
  • AccountingHigh-margin technology portfolio with softer cashNote
  • Insiders1 purchases and 4 salesOK

Business

Fortive owns operating-technology and healthcare-technology businesses.

Where the revenue comes from

Fiscal 2025, as Fortive Corp reports it. History and quarterly detail are in the app.

  • Intelligent Operating Solutions$2.9B
  • Advanced Healthcare Solutions$1.3B

Leadership changes

From Fortive Corp's own filings, the day they're filed.

  • Mark D. Okerstrom · President · appointmenteff. 2025-03-24
  • Charles E. McLaughlin · President · appointmenteff. 2025-03-24
  • Gregory J. Moore · Directors · appointmenteff. 2025-02-26

Latest filings

  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-06-11
  • 8-K · Company announcement2026-05-14
  • 10-Q · Quarterly report2026-04-30
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Fortive Corp, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.